Anzeige
Erschienen in:
03.10.2023 | Practical Issues and Updates
Manage idiopathic hypersomnia with a combination of non-pharmacological and pharmacological treatments
Erschienen in: Drugs & Therapy Perspectives | Ausgabe 11/2023
Einloggen, um Zugang zu erhaltenAbstract
Idiopathic hypersomnia (IH) is a rare sleeping disorder that is difficult to diagnose, and little is known about its pathophysiology. A defining symptom of IH is excessive daytime sleepiness, which can manifest as narcolepsy-like episodes or as continuous sleepiness. Other symptoms of IH includes sleep inertia and cognitive impairment. Currently, calcium, magnesium, potassium and sodium oxybates is the only FDA approved pharmacological treatment option in the management of IH. Off-label treatment options are recommended by guidelines, with many also being used for the management of narcolepsy.